Evaluation of the immunogenicity and safety of a commercially available vaccine when co-administered with GlaxoSmithKline Biologicals' HPV vaccine (580299) in healthy female subjects

Trial Profile

Evaluation of the immunogenicity and safety of a commercially available vaccine when co-administered with GlaxoSmithKline Biologicals' HPV vaccine (580299) in healthy female subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Hepatitis B vaccine recombinant
  • Indications Cervical cancer; Hepatitis B; Human papillomavirus infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Sep 2011 Results published in Clinical and Vaccine Immunology.
    • 01 Jul 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
    • 30 Oct 2008 Planned end date changed from 1 Oct 2009 to 1 Jul 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top